Genomic Evolution of Breast Cancer Metastasis and Relapse.

Autor:	Yates LR; Wellcome Trust Sanger Institute, Hinxton CB10 1SA, UK; Department of Clinical Oncology, Guys and St Thomas' NHS Trust, London SE1 9RT, UK., Knappskog S; Section of Oncology, Department of Clinical Science, University of Bergen, Bergen, Norway; Department of Oncology, Haukeland University Hospital, Bergen, Norway., Wedge D; Wellcome Trust Sanger Institute, Hinxton CB10 1SA, UK; Big Data Institute, University of Oxford, Oxford OX3 7BN, UK., Farmery JHR; Cancer Research UK Cambridge Institute, University of Cambridge, Li Ka Shing Centre, Robinson Way, Cambridge CB2 0RE, UK., Gonzalez S; Wellcome Trust Sanger Institute, Hinxton CB10 1SA, UK; European Bioinformatics Institute EMBL-EBI, Wellcome Genome Campus, Hinxton CB10 1SD, UK., Martincorena I; Wellcome Trust Sanger Institute, Hinxton CB10 1SA, UK., Alexandrov LB; Theoretical Biology and Biophysics (T-6), Los Alamos National Laboratory, Los Alamos, NM 87545, USA; Center for Nonlinear Studies, Los Alamos National Laboratory, Los Alamos, NM 87545, USA; University of New Mexico Comprehensive Cancer Center, Albuquerque, NM 87102, USA., Van Loo P; The Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK; Department of Human Genetics, University of Leuven, 3000 Leuven, Belgium., Haugland HK; Department of Pathology, Haukeland University Hospital, Bergen, Norway; The Gade Laboratory for Pathology, Department of Clinical Medicine, University of Bergen, Bergen, Norway., Lilleng PK; Department of Pathology, Haukeland University Hospital, Bergen, Norway; The Gade Laboratory for Pathology, Department of Clinical Medicine, University of Bergen, Bergen, Norway., Gundem G; Wellcome Trust Sanger Institute, Hinxton CB10 1SA, UK; Computational Oncology, Epidemiology and Biostatistics Memorial Sloan Kettering Cancer Institute, New York, NY 10065 USA., Gerstung M; Wellcome Trust Sanger Institute, Hinxton CB10 1SA, UK; European Bioinformatics Institute EMBL-EBI, Wellcome Genome Campus, Hinxton CB10 1SD, UK., Pappaemmanuil E; Wellcome Trust Sanger Institute, Hinxton CB10 1SA, UK; Computational Oncology, Epidemiology and Biostatistics Memorial Sloan Kettering Cancer Institute, New York, NY 10065 USA., Gazinska P; Division of Cancer Studies, Faculty of Life Sciences and Medicine, King's College London, London SE1 9RT, UK., Bhosle SG; Wellcome Trust Sanger Institute, Hinxton CB10 1SA, UK., Jones D; Wellcome Trust Sanger Institute, Hinxton CB10 1SA, UK., Raine K; Wellcome Trust Sanger Institute, Hinxton CB10 1SA, UK., Mudie L; Wellcome Trust Sanger Institute, Hinxton CB10 1SA, UK., Latimer C; Wellcome Trust Sanger Institute, Hinxton CB10 1SA, UK., Sawyer E; Department of Clinical Oncology, Guys and St Thomas' NHS Trust, London SE1 9RT, UK; Division of Cancer Studies, Faculty of Life Sciences and Medicine, King's College London, London SE1 9RT, UK., Desmedt C; Breast Cancer Translational Research Laboratory, Université Libre de Bruxelles, Institut Jules Bordet, Bd de Waterloo 121, 1000 Brussels, Belgium., Sotiriou C; Breast Cancer Translational Research Laboratory, Université Libre de Bruxelles, Institut Jules Bordet, Bd de Waterloo 121, 1000 Brussels, Belgium., Stratton MR; Wellcome Trust Sanger Institute, Hinxton CB10 1SA, UK., Sieuwerts AM; Erasmus MC Cancer Institute and Cancer Genomics Netherlands, Erasmus University Medical Center, Department of Medical Oncology, Rotterdam, the Netherlands., Lynch AG; Cancer Research UK Cambridge Institute, University of Cambridge, Li Ka Shing Centre, Robinson Way, Cambridge CB2 0RE, UK., Martens JW; Erasmus MC Cancer Institute and Cancer Genomics Netherlands, Erasmus University Medical Center, Department of Medical Oncology, Rotterdam, the Netherlands., Richardson AL; Department of Pathology, Brigham and Women's Hospital, Boston, MA 02115, USA; Dana-Farber Cancer Institute, Boston, MA 02215, USA., Tutt A; Division of Cancer Studies, Faculty of Life Sciences and Medicine, King's College London, London SE1 9RT, UK; Breast Cancer Now Research Unit, King's College London, London SE1 9RT, UK; The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London SW3 6JB, UK., Lønning PE; Section of Oncology, Department of Clinical Science, University of Bergen, Bergen, Norway; Department of Oncology, Haukeland University Hospital, Bergen, Norway. Electronic address: per.eystein.lonning@helse-bergen.no., Campbell PJ; Wellcome Trust Sanger Institute, Hinxton CB10 1SA, UK. Electronic address: pc8@sanger.ac.uk.
Jazyk:	angličtina
Zdroj:	Cancer cell [Cancer Cell] 2017 Aug 14; Vol. 32 (2), pp. 169-184.e7.
DOI:	10.1016/j.ccell.2017.07.005
Abstrakt:	Patterns of genomic evolution between primary and metastatic breast cancer have not been studied in large numbers, despite patients with metastatic breast cancer having dismal survival. We sequenced whole genomes or a panel of 365 genes on 299 samples from 170 patients with locally relapsed or metastatic breast cancer. Several lines of analysis indicate that clones seeding metastasis or relapse disseminate late from primary tumors, but continue to acquire mutations, mostly accessing the same mutational processes active in the primary tumor. Most distant metastases acquired driver mutations not seen in the primary tumor, drawing from a wider repertoire of cancer genes than early drivers. These include a number of clinically actionable alterations and mutations inactivating SWI-SNF and JAK2-STAT3 pathways. (Copyright © 2017 The Authors. Published by Elsevier Inc. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu